Increasing Soluble P-Selectin Levels Predict Higher Peripheral Atherosclerotic Plaque Progression.
3D ultrasonography
P-selectin
atherosclerosis
plaque progression
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
10 Oct 2023
10 Oct 2023
Historique:
received:
20
09
2023
revised:
06
10
2023
accepted:
07
10
2023
medline:
28
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
The adhesion molecule P-selectin is expressed by endothelial cells and platelets. It is involved in platelet activation and leukocyte adhesion, both important processes in the pathogenesis of atherosclerosis. Our study was designed to assess the predictive value of soluble P-selectin (sP-selectin) on the progression of peripheral atherosclerosis. This is an observational, single-center, cohort study that included 443 patients with established cardiovascular disease (CVD) or at least one cardiovascular risk factor. Over a period of 4 years, each patient underwent three-dimensional (3D) ultrasound to assess the plaque volume of the carotid and femoral arteries once per year. In addition, plasma sP-selectin levels were measured at each visit. The association between changes in sP-selectin and peripheral atherosclerotic plaque progression was assessed using growth curve models. 338 patients were available for statistical analysis. Each standard deviation increase in sP-selectin was significantly ( Increasing sP-selectin levels can predict higher atherosclerotic plaque progression as measured by 3D ultrasound. We suggest serial measurements of sP-selectin as an easily measurable biomarker for peripheral atherosclerotic plaque progression.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
The adhesion molecule P-selectin is expressed by endothelial cells and platelets. It is involved in platelet activation and leukocyte adhesion, both important processes in the pathogenesis of atherosclerosis. Our study was designed to assess the predictive value of soluble P-selectin (sP-selectin) on the progression of peripheral atherosclerosis.
METHODS
METHODS
This is an observational, single-center, cohort study that included 443 patients with established cardiovascular disease (CVD) or at least one cardiovascular risk factor. Over a period of 4 years, each patient underwent three-dimensional (3D) ultrasound to assess the plaque volume of the carotid and femoral arteries once per year. In addition, plasma sP-selectin levels were measured at each visit. The association between changes in sP-selectin and peripheral atherosclerotic plaque progression was assessed using growth curve models.
RESULTS
RESULTS
338 patients were available for statistical analysis. Each standard deviation increase in sP-selectin was significantly (
CONCLUSIONS
CONCLUSIONS
Increasing sP-selectin levels can predict higher atherosclerotic plaque progression as measured by 3D ultrasound. We suggest serial measurements of sP-selectin as an easily measurable biomarker for peripheral atherosclerotic plaque progression.
Identifiants
pubmed: 37892568
pii: jcm12206430
doi: 10.3390/jcm12206430
pmc: PMC10607706
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Bank of Austria
ID : 15656
Références
Atheroscler Plus. 2021 Sep 21;45:10-17
pubmed: 36643995
Curr Atheroscler Rep. 2020 May 26;22(5):19
pubmed: 32458165
Circulation. 2001 Jan 30;103(4):491-5
pubmed: 11157711
Am J Pathol. 1994 May;144(5):952-61
pubmed: 7513951
Eur Heart J. 2020 Sep 1;41(33):3156-3165
pubmed: 31898723
Can J Cardiol. 2022 Jan;38(1):92-101
pubmed: 34737035
J Clin Med. 2018 Dec 31;8(1):
pubmed: 30602707
J Clin Med. 2020 Aug 31;9(9):
pubmed: 32878068
J Am Coll Cardiol. 2021 Jul 13;78(2):156-179
pubmed: 34238438
Thromb Haemost. 2021 Dec;121(12):1637-1649
pubmed: 33984869
Circulation. 2020 Aug 18;142(7):621-642
pubmed: 32546049
Eur Heart J. 2021 Sep 7;42(34):3227-3337
pubmed: 34458905
Cerebrovasc Dis. 2012;34(4):290-6
pubmed: 23128470
Int J Cardiol. 2006 Jan 13;106(2):183-90
pubmed: 16321690
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
J Thromb Thrombolysis. 2021 Apr;51(3):675-681
pubmed: 32683645
Nature. 2021 Jan;589(7841):287-292
pubmed: 33268892
Eur Heart J. 2015 Oct 14;36(39):2635-42
pubmed: 26049157
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
J Atheroscler Thromb. 2009 Aug;16(4):339-45
pubmed: 19672031
J Am Coll Cardiol. 2013 May 21;61(20):2048-55
pubmed: 23500230
Curr Opin Lipidol. 2006 Oct;17(5):495-501
pubmed: 16960497
Atherosclerosis. 2015 Apr;239(2):405-11
pubmed: 25682040
J Diabetes. 2020 Feb;12(2):102-104
pubmed: 31411812
J Thromb Haemost. 2022 May;20(5):1056-1066
pubmed: 35243742
JACC Cardiovasc Imaging. 2012 Jul;5(7):681-9
pubmed: 22789936
Stroke. 2006 Jan;37(1):87-92
pubmed: 16339465
Eur Heart J. 2003 Jun;24(11):987-1003
pubmed: 12788299
J Clin Invest. 1997 Mar 1;99(5):1037-43
pubmed: 9062362
Atherosclerosis. 2012 Jan;220(1):128-33
pubmed: 21764060
Biochem Cell Biol. 2020 Apr;98(2):120-129
pubmed: 31063699
Eur J Clin Invest. 2019 Sep;49(9):e13157
pubmed: 31318979
Blood. 2017 Sep 28;130(13):1499-1506
pubmed: 28807983
BMC Cardiovasc Disord. 2020 Aug 24;20(1):387
pubmed: 32831023
Int J Mol Sci. 2021 Jul 26;22(15):
pubmed: 34360707
N Engl J Med. 2011 Jul 21;365(3):213-21
pubmed: 21774709
N Engl J Med. 2012 Oct 4;367(14):1310-20
pubmed: 23034020
J Atheroscler Thromb. 2021 May 1;28(5):435-453
pubmed: 33583910
Cells. 2020 Mar 01;9(3):
pubmed: 32121535